NCI-MATCH — Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH, EAY131)

Phase 2 · 2015 · Solid Tumors, Lymphoma

Design

Large-scale, tumor-agnostic, genomically-matched precision-oncology umbrella/basket trial assigning patients to molecularly targeted treatment arms based on actionable tumor alterations.

Population

Adults with advanced solid tumors, lymphomas, or myeloma that progressed on standard therapy, screened by centralized tumor genomic profiling across tumor types.

Primary Endpoint

Objective response rate (per treatment arm)

Key Result

Of 5,954 patients with sequencing results, actionable alterations were identified in 37.6% and 17.8% were assigned to a treatment arm, demonstrating feasibility of nationwide genomically-matched therapy assignment.

Guideline Impact

Advanced adoption of tumor-agnostic, biomarker-matched treatment paradigms in precision oncology.